메뉴 건너뛰기




Volumn 11, Issue 2, 2011, Pages 81-92

Trastuzumab and beyond: Sequencing cancer genomes and predicting molecular networks

Author keywords

biomarkers; breast gastric cancer; cancer genome; drugs; systems biology; trastuzumab

Indexed keywords

AFATINIB; AMG 888; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERTUMAXOMAB; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; LAPATINIB; MITOCHONDRIAL DNA; MONOCLONAL ANTIBODY; NERATINIB; NOTCH RECEPTOR; PERTUZUMAB; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; RETASPIMYCIN; TANESPIMYCIN; TRANSFORMING GROWTH FACTOR; TRASTUZUMAB; U3 1287; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VARLITINIB; VASCULOTROPIN; WNT PROTEIN;

EID: 79953066553     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.81     Document Type: Review
Times cited : (120)

References (94)
  • 1
    • 0021242388 scopus 로고
    • Tumor heterogeneity
    • Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259-2265. (Pubitemid 14110633)
    • (1984) Cancer Research , vol.44 , Issue.6 , pp. 2259-2265
    • Heppner, G.H.1
  • 2
    • 0034614637 scopus 로고    scopus 로고
    • The hallmarks of cancer
    • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
    • (2000) Cell , vol.100 , Issue.1 , pp. 57-70
    • Hanahan, D.1    Weinberg, R.A.2
  • 4
    • 52149123619 scopus 로고    scopus 로고
    • Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    • Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
    • (2008) Science , vol.321 , pp. 1801-1806
    • Jones, S.1    Zhang, X.2    Parsons, D.W.3
  • 6
    • 76249121728 scopus 로고    scopus 로고
    • Review. Time for the epigenome
    • Review. Time for the epigenome. Nature 2010; 463: 587.
    • (2010) Nature , vol.463 , pp. 587
  • 9
    • 55549101623 scopus 로고    scopus 로고
    • DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
    • Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
    • (2008) Nature , vol.456 , pp. 66-72
    • Ley, T.J.1    Mardis, E.R.2    Ding, L.3    Fulton, B.4    McLellan, M.D.5    Chen, K.6
  • 12
    • 77951139631 scopus 로고    scopus 로고
    • Genome remodelling in a basal-like breast cancer metastasis and xenograft
    • Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
    • (2010) Nature , vol.464 , pp. 999-1005
    • Ding, L.1    Ellis, M.J.2    Li, S.3    Larson, D.E.4    Chen, K.5    Wallis, J.W.6
  • 14
    • 0036561908 scopus 로고    scopus 로고
    • Modelling the molecular circuitry of cancer
    • Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-341. (Pubitemid 37328946)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.5 , pp. 331-341
    • Hahn, W.C.1    Weinberg, R.A.2
  • 15
    • 63049104211 scopus 로고    scopus 로고
    • Microenvironmental regulation of metastasis
    • Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
    • (2009) Nat Rev Cancer , vol.9 , pp. 239-252
    • Joyce, J.A.1    Pollard, J.W.2
  • 16
    • 77949613884 scopus 로고    scopus 로고
    • Systems medicine: A real approach for future personalized oncology?
    • Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 2010; 11: 283-287.
    • (2010) Pharmacogenomics , vol.11 , pp. 283-287
    • Roukos, D.H.1
  • 17
    • 70249134919 scopus 로고    scopus 로고
    • Molecular networks as sensors and drivers of common human diseases
    • Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009; 461: 218-223.
    • (2009) Nature , vol.461 , pp. 218-223
    • Schadt, E.E.1
  • 18
    • 74749106342 scopus 로고    scopus 로고
    • Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care
    • Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 2010; 10: 33-48.
    • (2010) Expert Rev Mol Diagn , vol.10 , pp. 33-48
    • Roukos, D.H.1
  • 19
    • 57649124192 scopus 로고    scopus 로고
    • Reverse engineering the genotype-phenotype map with natural genetic variation
    • Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 2008; 456: 738-744.
    • (2008) Nature , vol.456 , pp. 738-744
    • Rockman, M.V.1
  • 20
    • 33646568784 scopus 로고    scopus 로고
    • Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
    • DOI 10.1200/JCO.2005.05.2308
    • Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150. (Pubitemid 46655601)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.14 , pp. 2137-2150
    • Kamangar, F.1    Dores, G.M.2    Anderson, W.F.3
  • 22
    • 11144242211 scopus 로고    scopus 로고
    • Timeline: Chemotherapy and the war on cancer
    • Chabner BA, Roberts Jr TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
    • (2005) Nat Rev Cancer , vol.5 , pp. 65-72
    • Chabner, B.A.1    Roberts Jr., T.G.2
  • 23
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 24
    • 77952304670 scopus 로고    scopus 로고
    • Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch DLD2 trial
    • Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch DLD2 trial. Lancet Oncol 2010; 11: 439-449.
    • (2010) Lancet Oncol , vol.11 , pp. 439-449
    • Songun, I.1    Putter, H.2    Kranenbarg, E.M.3    Sasako, M.4    Van De Velde, C.J.5
  • 26
    • 0035818048 scopus 로고    scopus 로고
    • Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-esophageal junction
    • Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-esophageal junction. N Engl J Med 2001; 345: 725-730.
    • (2001) N Engl J Med , vol.345 , pp. 725-730
    • MacDonald, J.S.1    Smalley, S.R.2    Benedetti, J.3    Hundahl, S.A.4    Estes, N.C.5    Stemmermann, G.N.6
  • 28
    • 62149146888 scopus 로고    scopus 로고
    • Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer
    • Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 2009; 16: 795-798.
    • (2009) Ann Surg Oncol , vol.16 , pp. 795-798
    • Roukos, D.H.1
  • 32
    • 4544374528 scopus 로고    scopus 로고
    • BRCA1 and BRCA2: 1994 and beyond
    • DOI 10.1038/nrc1431
    • Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676. (Pubitemid 39215065)
    • (2004) Nature Reviews Cancer , vol.4 , Issue.9 , pp. 665-676
    • Narod, S.A.1    Foulkes, W.D.2
  • 33
    • 73349135021 scopus 로고    scopus 로고
    • CDH1 testing: Can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?
    • Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 2009; 16: 2678-2681.
    • (2009) Ann Surg Oncol , vol.16 , pp. 2678-2681
    • Ziogas, D.1    Roukos, D.H.2
  • 34
    • 85047686032 scopus 로고    scopus 로고
    • Genome-wide association studies: How predictable is a person's cancer risk?
    • Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther 2009; 9: 389-392.
    • (2009) Expert Rev Anticancer Ther , vol.9 , pp. 389-392
    • Roukos, D.H.1
  • 35
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: Targets for cancer therapy
    • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370. (Pubitemid 38579482)
    • (2004) Nature Reviews Cancer , vol.4 , Issue.5 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 36
    • 67649472398 scopus 로고    scopus 로고
    • Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3
    • Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475.
    • (2009) Nat Rev Cancer , vol.9 , pp. 463-475
    • Baselga, J.1    Swain, S.M.2
  • 38
    • 70350204423 scopus 로고    scopus 로고
    • Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
    • (abstr LBA4509)
    • Van Cutsem E, Kang Y, Chung H, Shen A, Sawaki F, Lordick J et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27(Suppl): 18s (abstr LBA4509).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Van Cutsem, E.1    Kang, Y.2    Chung, H.3    Shen, A.4    Sawaki, F.5    Lordick, J.6
  • 39
    • 74649083025 scopus 로고    scopus 로고
    • Targeting gastric cancer with trastuzumab: New clinical practice and innovative developments to overcome resistance
    • Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 2010; 17: 14-17.
    • (2010) Ann Surg Oncol , vol.17 , pp. 14-17
    • Roukos, D.H.1
  • 40
    • 73349121354 scopus 로고    scopus 로고
    • Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology
    • Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C et al. Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology. J Clin Oncol 2009; 27: 6052-6069.
    • (2009) J Clin Oncol , vol.27 , pp. 6052-6069
    • Petrelli, N.J.1    Winer, E.P.2    Brahmer, J.3    Dubey, S.4    Smith, S.5    Thomas, C.6
  • 41
    • 26844457534 scopus 로고    scopus 로고
    • The distinctive nature of HER2-positive breast cancers
    • DOI 10.1056/NEJMp058197
    • Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654. (Pubitemid 41464703)
    • (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1652-1654
    • Burstein, H.J.1
  • 42
    • 26844559765 scopus 로고    scopus 로고
    • Trastuzumab in the treatment of breast cancer
    • DOI 10.1056/NEJMe058196
    • Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 1734-1736. (Pubitemid 41464714)
    • (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1734-1736
    • Hortobagyi, G.N.1
  • 44
    • 36148961294 scopus 로고    scopus 로고
    • Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
    • Perez EA, Romond EH, Suman VJ, Jeong NE, Davidson CE, Geyer S et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25: 512.
    • (2007) J Clin Oncol , vol.25 , pp. 512
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3    Jeong, N.E.4    Davidson, C.E.5    Geyer, S.6
  • 47
    • 33947317453 scopus 로고    scopus 로고
    • BCIRG 006: II interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxo-rubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel carboplatin and trastuzumab in Her2neu positive early breast cancer patients
    • December 14-17 San Antonio, Texas
    • Slamon D, Eiermann W, Robert NJ, Pienkowski T, Martin M, Pawlicki M et al. BCIRG 006: II interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxo-rubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. The 2006 San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
    • (2006) The 2006 San Antonio Breast Cancer Symposium
    • Slamon, D.1    Eiermann, W.2    Robert, N.J.3    Pienkowski, T.4    Martin, M.5    Pawlicki, M.6
  • 48
    • 33645720799 scopus 로고    scopus 로고
    • Phase III randomized trial comparing doxorubicin and cyclo-phosphamide followed by docetaxel with doxorubicin and cyclo-phosphamide followed by docetaxel and trastuzumab with docetaxel carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study
    • December 8-11 San Antonio, Texas
    • Slamon D, Eiermann W, Robert NJ, Pienkowski T, Martin M, Pawlicki M et al. Phase III randomized trial comparing doxorubicin and cyclo-phosphamide followed by docetaxel with doxorubicin and cyclo-phosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. The 2005 San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Texas.
    • (2005) The 2005 San Antonio Breast Cancer Symposium
    • Slamon, D.1    Eiermann, W.2    Robert, N.J.3    Pienkowski, T.4    Martin, M.5    Pawlicki, M.6
  • 50
    • 46149111250 scopus 로고    scopus 로고
    • Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
    • DOI 10.1634/theoncologist.2008-0001
    • Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 13: 620-630. (Pubitemid 351904907)
    • (2008) Oncologist , vol.13 , Issue.6 , pp. 620-630
    • Dahabreh, I.J.1    Linardou, H.2    Siannis, F.3    Fountzilas, G.4    Murray, S.5
  • 51
    • 58149354867 scopus 로고    scopus 로고
    • Quo vadis with targeted drugs in the 21st century?
    • Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009; 27: 2-5.
    • (2009) J Clin Oncol , vol.27 , pp. 2-5
    • Bergh, J.1
  • 52
    • 66749140976 scopus 로고    scopus 로고
    • Mea culpa with cancer-targeted therapy: New thinking and new agents design for novel, causal networks-based, personalized biomedicine
    • Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 2009; 9: 217-221.
    • (2009) Expert Rev Mol Diagn , vol.9 , pp. 217-221
    • Roukos, D.H.1
  • 53
    • 24944578615 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out?
    • Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 2005; 23: 5856-5858.
    • (2005) J Clin Oncol , vol.23 , pp. 5856-5858
    • Gandara, D.R.1    Gumerlock, P.H.2
  • 54
    • 70349472886 scopus 로고    scopus 로고
    • New, but not improved? Incorporating comparative-effectiveness information into FDA labeling
    • Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med 2009; 361: 1230-1233.
    • (2009) N Engl J Med , vol.361 , pp. 1230-1233
    • Stafford, R.S.1    Wagner, T.H.2    Lavori, P.W.3
  • 56
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121.
    • (2010) Lancet Oncol , vol.11 , pp. 121
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3    Negoro, S.4    Okamoto, I.5    Tsurutani, J.6
  • 57
    • 66249090533 scopus 로고    scopus 로고
    • Systems biology: When it is time to die
    • Bastiaens P. Systems biology: when it is time to die. Nature 2009; 459: 334-335.
    • (2009) Nature , vol.459 , pp. 334-335
    • Bastiaens, P.1
  • 58
    • 70350593945 scopus 로고    scopus 로고
    • Current concerns and challenges towards tailored anti-angiogenic therapy in cancer
    • Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009; 9: 1413-1416.
    • (2009) Expert Rev Anticancer Ther , vol.9 , pp. 1413-1416
    • Roukos, D.H.1    Tzakos, A.2    Zografos, G.3
  • 59
    • 62649101158 scopus 로고    scopus 로고
    • Cancer: The nuances of therapy
    • Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 2009; 458: 290-292.
    • (2009) Nature , vol.458 , pp. 290-292
    • Ellis, L.M.1    Reardon, D.A.2
  • 61
    • 70449641339 scopus 로고    scopus 로고
    • Isolated tumor cells in breast cancer
    • Roukos DH. Isolated tumor cells in breast cancer. N Engl J Med 2009; 361: 1994-1995.
    • (2009) N Engl J Med , vol.361 , pp. 1994-1995
    • Roukos, D.H.1
  • 62
    • 60849097255 scopus 로고    scopus 로고
    • Gene-expression signatures in breast cancer
    • Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
    • (2009) N Engl J Med , vol.360 , pp. 790-800
    • Sotiriou, C.1    Pusztai, L.2
  • 65
    • 62449163752 scopus 로고    scopus 로고
    • Twenty-one-gene assay: Challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer
    • Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 2009; 27: 1337-1338.
    • (2009) J Clin Oncol , vol.27 , pp. 1337-1338
    • Roukos, D.H.1
  • 66
    • 33746887084 scopus 로고    scopus 로고
    • Molecular signatures predict outcomes of breast cancer
    • DOI 10.1056/NEJMe068145
    • O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med 2006; 355: 615-617. (Pubitemid 44200656)
    • (2006) New England Journal of Medicine , vol.355 , Issue.6 , pp. 615-617
    • O'Shaughnessy, J.A.1
  • 68
    • 77951650701 scopus 로고    scopus 로고
    • HER2 signatures in breast cancer: Ready to go to print?
    • Eichhorn PJ, Baselga J. HER2 signatures in breast cancer: ready to go to print? J Clin Oncol 2010; 28: 1809-1810.
    • (2010) J Clin Oncol , vol.28 , pp. 1809-1810
    • Eichhorn, P.J.1    Baselga, J.2
  • 69
    • 79953058756 scopus 로고    scopus 로고
    • Individualized Patients Personalized Care PIPC: Washington, DC (Accessed April 17, 2009)
    • Partnership to Improve Patient Care. Individualized Patients Personalized Care 2009. PIPC: Washington, DC http://www.improvepatientcare.org/ individualized-patients-personalized-care (Accessed April 17, 2009).
    • (2009) Partnership to Improve Patient Care
  • 70
    • 53649106195 scopus 로고    scopus 로고
    • Next-generation DNA sequencing
    • Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145.
    • (2008) Nat Biotechnol , vol.26 , pp. 1135-1145
    • Shendure, J.1    Ji, H.2
  • 71
    • 77950607162 scopus 로고    scopus 로고
    • Bionetworks-based personalized medicine vs comparative-effectiveness research or harmonization of both in cancer management?
    • Roukos DH. Bionetworks-based personalized medicine vs comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 2010; 10: 247-250.
    • (2010) Expert Rev Mol Diagn , vol.10 , pp. 247-250
    • Roukos, D.H.1
  • 72
    • 75749155513 scopus 로고    scopus 로고
    • Valid concerns
    • Valid concerns. Nature 2010; 463: 401-402.
    • (2010) Nature , vol.463 , pp. 401-402
  • 73
    • 73849149841 scopus 로고    scopus 로고
    • 2020 visions personalized medicine
    • Goldstein DB. 2020 visions personalized medicine. Nature 2010; 463: 27.
    • (2010) Nature , vol.463 , pp. 27
    • Goldstein, D.B.1
  • 74
    • 56449111358 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
    • Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
    • (2008) Cancer Res , vol.68 , pp. 9221-9230
    • Eichhorn, P.J.1    Gili, M.2    Scaltriti, M.3    Serra, V.4    Guzman, M.5    Nijkamp, W.6
  • 77
    • 49149112491 scopus 로고    scopus 로고
    • Risk factors for the incidence of breast cancer: Do they affect survival from the disease?
    • Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26: 3310-3316.
    • (2008) J Clin Oncol , vol.26 , pp. 3310-3316
    • Barnett, G.C.1    Shah, M.2    Redman, K.3    Easton, D.F.4    Ponder, B.A.5    Pharoah, P.D.6
  • 80
    • 0019183253 scopus 로고
    • On the nature of susceptibility to cancer. The presidential address
    • Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer 1980; 46: 1307-1318. (Pubitemid 11253510)
    • (1980) Cancer , vol.46 , Issue.6 , pp. 1307-1318
    • Miller, D.G.1
  • 81
    • 38449094794 scopus 로고    scopus 로고
    • Oncogenic transformation and experimental models of human cancer
    • DOI 10.2741/2661
    • Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front Biosci 2008; 13: 71-84. (Pubitemid 351594764)
    • (2008) Frontiers in Bioscience , vol.13 , Issue.1 , pp. 71-84
    • Schinzel, A.C.1    Hahn, W.C.2
  • 83
    • 69449090120 scopus 로고    scopus 로고
    • Panel members. Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009
    • Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
    • (2009) Ann Oncol , vol.20 , pp. 1319-1329
    • Goldhirsch, A.1    Ingle, J.N.2    Gelber, R.D.3    Coates, A.S.4    Thürlimann, B.5    Senn, H.J.6
  • 84
    • 76749112093 scopus 로고    scopus 로고
    • From tumor size and HER2 status to systems oncology for very early breast cancer treatment
    • Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 2010; 10: 123-128.
    • (2010) Expert Rev Anticancer Ther , vol.10 , pp. 123-128
    • Roukos, D.H.1    Ziogas, D.2
  • 85
    • 70349667568 scopus 로고    scopus 로고
    • Drug discovery: Propping up a destructive regime
    • Peterson RT. Drug discovery: propping up a destructive regime. Nature 2009; 461: 599-600.
    • (2009) Nature , vol.461 , pp. 599-600
    • Peterson, R.T.1
  • 86
    • 70449659897 scopus 로고    scopus 로고
    • Chemical biology: A notch above other inhibitors
    • Arora PS, Ansari AZ. Chemical biology: a notch above other inhibitors. Nature 2009; 462: 171-173.
    • (2009) Nature , vol.462 , pp. 171-173
    • Arora, P.S.1    Ansari, A.Z.2
  • 87
    • 77950412216 scopus 로고    scopus 로고
    • The human genome at ten
    • The human genome at ten. Nature 2010; 464: 649-650.
    • (2010) Nature , vol.464 , pp. 649-650
  • 88
    • 77950440741 scopus 로고    scopus 로고
    • Has the revolution arrived?
    • Collins F. Has the revolution arrived? Nature 2010; 464: 674-675.
    • (2010) Nature , vol.464 , pp. 674-675
    • Collins, F.1
  • 89
    • 77950456427 scopus 로고    scopus 로고
    • Multiple personal genomes await
    • Venter JC. Multiple personal genomes await. Nature 2010; 464: 676-677.
    • (2010) Nature , vol.464 , pp. 676-677
    • Venter, J.C.1
  • 90
    • 77950448106 scopus 로고    scopus 로고
    • Point: Hypotheses first
    • Weinberg R. Point: hypotheses first. Nature 2010; 464: 678.
    • (2010) Nature , vol.464 , pp. 678
    • Weinberg, R.1
  • 91
    • 77950441808 scopus 로고    scopus 로고
    • Counterpoint: Data first
    • Golub T. Counterpoint: data first. Nature 2010; 464: 679.
    • (2010) Nature , vol.464 , pp. 679
    • Golub, T.1
  • 92
    • 77952509768 scopus 로고    scopus 로고
    • Human genome at ten: The sequence explosion
    • Human genome at ten: the sequence explosion. Nature 2010; 464: 670-671.
    • (2010) Nature , vol.464 , pp. 670-671
  • 93
    • 77950393253 scopus 로고    scopus 로고
    • Human genome at ten: The human race
    • Abbott A. Human genome at ten: the human race. Nature 2010; 464: 668-669.
    • (2010) Nature , vol.464 , pp. 668-669
    • Abbott, A.1
  • 94
    • 77950398306 scopus 로고    scopus 로고
    • Human genome at ten: Life is complicated
    • Check Hayden E. Human genome at ten: life is complicated. Nature 2010; 464: 664-667.
    • (2010) Nature , vol.464 , pp. 664-667
    • Check Hayden, E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.